Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 5 Shows a paired comparison of baseline scores and post duloxetine and post placebo in group B

From: Daily intake of 30 mg duloxetine is effective in decreasing premature ejaculation severity: a prospective randomized placebo-controlled cross over clinical trial

Group B

Baseline

After placebo

p-value

Baseline

After duloxetine

p-value

Median

IQR

Median

IQR

Median

IQR

Median

IQR

AIPEa

19.5

8–30

19.5

8–30

1.000

19.5

8–30

26

14–34

 < 0.001d

IELT(Sec)b

60

30–120

60

30–120

1.000

60

30–120

240

120–240

 < 0.001d

Male SQOLc

20

16–34

21

16–33

1.000

21

16–33

40

30–55

 < 0.001d

  1. aAIPE the Arabic index of premature ejaculation
  2. bIELT Intravaginal ejaculatory latency time
  3. cMale SQOL (sexual quality of life questionnaire- male version) before and after treatment group B
  4. dP value was calculated using Wilcoxon sign rank test
Back to article page

Basic and Clinical Andrology

ISSN: 2051-4190